C4 Therapeutics (CCCC) Cash from Operations (2019 - 2026)

C4 Therapeutics' Cash from Operations history runs 8 years deep, the most recent figure standing at 29944000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 10.04% year-over-year to 29944000.0 in Q1 2026; TTM through Mar 2026 was 95353000.0, a 18.71% decrease from a year earlier, with the FY2025 full-year figure at 98694000.0, down 51.47% from the prior year.
• Cash from Operations fell to 29944000.0 in Q1 2026 per CCCC's latest filing, from 22145000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 4974000.0 in Q2 2024 and bottomed at 33285000.0 in Q1 2025.
• The 5-year median for Cash from Operations is 24133000.0 (2024), against an average of 23916000.0.
• Across the five-year window, Cash from Operations soared 73.82% in 2024 and sank 142.4% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 29128000.0 in 2022, then advanced by 17.57% to 24009000.0 in 2023, then advanced by 25.31% to 17932000.0 in 2024, then fell by 23.49% to 22145000.0 in 2025, then sank by 35.22% to 29944000.0 in 2026.
• Per Business Quant, the three latest CCCC Cash from Operations figures stand at 29944000.0 (Q1 2026), 22145000.0 (Q4 2025), and 31207000.0 (Q3 2025).